In this Supplement
Experts share how the drug effect of Zilver PTX is changing SFA treatment.
What will be the workhorse therapy to address this disease over the next 3 to 5 years?
By Gary M. Ansel, MD; William A. Gray, MD; and Dierk Scheinert, MD
The importance of cost effectiveness in health care is accelerating. Implanting drug-eluting stents in the superficial femoral artery may offer a safe, effective, and economically valuable solution.
By Mark W. Burket, MD
Cook Medical Vice President Rob Lyles provides insight on the approval and launch process of Zilver PTX in the United States, as well as next steps in the evolution of drug-eluting therapies.
Experience with patients treated with Zilver PTX.